Issue 13

Injectable CDMO Market to Triple in the Next Decade

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Capitalizing on a Boom in Injectable Therapies

It wasn’t so very long ago that progress in delivering systemic treatments, via new oral technologies, inhalables, and via a plethora of alternative routes of delivery suggested that the days were numbered for invasive injections. But recent reports, and an apparently endless slew of capacity expansions and technological advances, now suggest that sterile injectables will remain a mainstay of drug delivery for some time to come. One report by ResearchAndMarkets.com predicts the global sterile injectable CDMO market is expected to more than treble from $11.1bn in 2024 to $33.7bn by 2034; a CAGR of 11.7%. 

Read more here.

FEATURED STORIES

Bora Aims to Expand U.S. Operations with Emergent Sterile Manufacturing Facility

Read more here.

Lupin Appoints CEO of New API CDMO Subsidiary

Read more here.

FDA Expands Label for Sarepta’s Duchenne Gene Therapy

Read more here.

Novo Nordisk Secures Approval in China for Obesity Drug Wegovy

Read more here.

Zealand Pharma Raises $1 Billion to Develop Obesity Drugs

Read more here.

NeuroBo Announces Successful Pre-Clinical Results, Raises $70 Million in Shares Sale for GLP-1

Read more here.

Abzena and Argonaut Partner to Promise Accelerated Drug Development Support

Read more here.

Lilly Looks to AI in Fight Against Drug-Resistant Bacteria

Read more here.

Formation Bio Secures $372 Million for AI-Driven Drug Development

Read more here.

FDA Issues Complete Response Letter for AbbVie’s Parkinson’s Treatment... Again

Read more here.

Ginkgo Bioworks Expands Layoffs to 400 Job Cuts

Read more here.